- FBR Capital upgraded Talbots (NYSE: TLB) to Outperform from Market Perform as it believes the company's inventory and SG&A control should help earnings and the stock's risk/reward is compelling at current levels. The firm raised its target on shares to $7 from $5.
- ThinkEquity upgraded Human Genome (NASDAQ: HGSI) to Buy from Accumulate to reflect higher assumptions for the company's Lupus treatment Benlysta. The firm raised its target on shares to $26 from $18.
- KeyBanc upgraded Parkway Properties (NYSE: PKY) to Buy from Hold based on valuation, improving fundamentals, and stable capital position. The firm has a $17 target on the stock.
- HSBC Holdings (NYSE: HBC) was upgraded to Overweight from Neutral at JPMorgan.
- BioScrip (NASDAQ: BIOS) was upgraded to Overweight from Neutral at Piper Jaffray.
- DISH Network (NASDAQ: DISH) was upgraded to Outperform from Neutral at Credit Suisse.
Analyst downgrades:
- Citigroup downgraded Extra Space Storage (NYSE: EXR) to Hold from Buy on concerns of declining fundamentals following the company's weaker than expected Q2 results. Citi raised its target on shares to $8.50 from $8.
- Jefferies downgraded Savient Pharmaceuticals (NASDAQ: SVNT) to Underperform from Hold as it believes the risk/reward on shares is unfavorable given uncertainties surrounding the timing of final approval for KRYSTEXXA. The firm has a $5 price target on the stock.
- Janney Montgomery downgraded Patriot Capital Funding (NASDAQ: PCAP) to Sell from Neutral after the company entered an acquisition agreement with Prospect Capital (NASDAQ: PSEC).
- France Telecom (NYSE: FTE) was downgraded to Neutral from Buy at BofA/Merrill.
- Aixtron (NASDAQ: AIXG) was downgraded to Neutral from Outperform at Credit Suisse.
- PharMerica (NYSE: PMC) was downgraded to Perform from Outperform at Oppenheimer.
Analyst initiations:
- Quiksilver (NYSE: ZQK) was reinstated with a Market Weight rating and $2.50 target at Thomas Weisel.
- Phase Forward (NASDAQ: PFWD) was initiated with a Hold rating and $16 target at Citigroup.
- Medidata Solutions (NASDAQ: MDSO) was initiated with an Outperform rating and $23 target at Credit Suisse, with a Buy rating and $22 target at Needham, and with a Hold rating and $21 target at Citigroup.
- Myriad Genetics (NASDAQ: MYGN) was initiated with an Outperform rating at William Blair.
- Air Products (NYSE: APD) was initiated with a Neutral rating and $86 target at Baird.
- Targacept (NASDAQ: TRGT) was initiated with a Buy rating at Ladenburg.











